Related Experiment Videos
Contraception in the patient with liver disease
1Department of Obstetrics and Gynecology, New England Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA.
Seminars in Perinatology
|June 25, 1998
Summary
Choosing contraception for women with liver disease requires careful consideration. Tubal ligation is an option for those with chronic liver disease who have finished childbearing, while progestin-only methods are generally safe for others.
Area of Science:
- Hepatology
- Gynecology
- Reproductive Health
Background:
- Contraception choices for patients with liver disease are complex.
- Hepatic function can influence the safety and efficacy of hormonal contraceptives.
- Existing guidelines require clarification for specific patient populations.
Purpose of the Study:
- To review and summarize current recommendations for contraceptive method selection in patients with liver disease.
- To identify safe and effective contraceptive options for women with varying degrees of hepatic impairment.
- To highlight contraindications and considerations for hormonal and non-hormonal contraception.
Main Methods:
- Literature review of studies on contraception and liver disease.
- Analysis of clinical guidelines and expert opinions.
- Synthesis of data regarding hormonal and non-hormonal contraceptive safety profiles.
Main Results:
- Tubal ligation is a recommended option for women with chronic liver disease who have completed childbearing.
- Estrogen-containing contraceptives are contraindicated in acute liver disease.
- Progestin-only contraceptives appear safe across various delivery systems.
- Barrier methods and intrauterine devices are generally suitable alternatives.
Conclusions:
- Contraceptive management in liver disease necessitates individualized assessment.
- Progestin-based methods and non-hormonal options offer safer alternatives to estrogen-containing contraceptives.
- Further research is needed to optimize contraceptive strategies for women with liver conditions.